{"schema_version":"secwatch.filing_event.v1","accession":"0001839998-24-000038","form_type":"8-K","ticker":null,"cik":"0001839998","company_name":"American Oncology Network, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.649643+00:00","generated_at":"2026-06-01T23:32:02.232859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"American Oncology Network Q1 revenue $364.3M (+20% YoY); net loss widens to $24.9M","bullets":["Revenue $364.3M, up 20% YoY from $303.7M; patient encounters grew 7.1%.","Net loss before non-controlling interest $24.9M vs $1.5M loss in Q1 2023.","Adjusted EBITDA $2.0M, down from $4.1M in prior-year quarter.","Added 17 new providers; expanded into Texas and Maryland markets.","Cost of revenue up 27.4% driven by higher drug costs and $13.3M equity-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001839998-24-000038","json":"https://secwatch.observer/filing/0001839998-24-000038.json","markdown":"https://secwatch.observer/filing/0001839998-24-000038.md","text":"https://secwatch.observer/filing/0001839998-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839998/000183999824000038/0001839998-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839998/000183999824000038/aonc-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:32:02.232859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23b63ae26e0322c68719705a4ffca6c8b6361f5b","claim":"American Oncology Network, Inc. reported First Quarter 2024 results: revenue $364.3 million, net income Net loss before non-controlling interest was $24.9 million.","evidence_excerpt":"Revenue was $364.3 million for the three-month period ended March 31, 2024, as compared to $303.7 million for the three-month period ended March 31, 2023, an increase of $60.6 million, or 20.0%. The overall increase was primarily attributable to increased patient encounters of 7.1% between the comparable periods, driving a $59.7 million increase in patient service revenue. This revenue growth was constrained in part by approximately $4.1 million of incremental implicit price concessions associated with accounts receivable in our legacy billing system as the Company transitioned its billing and collection efforts to a new billing system in the fourth quarter of 2023. For the three months ended March 31, 2024, cost of revenue increased $76.4 million, or 27.4%, which was primarily driven by higher drug and medical supply costs. Cost of revenue also includes equity-based compensation of $13.3 million for the quarter ended March 31, 2024, with no such costs incurred during the comparable ye","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1839998/000183999824000038/0001839998-24-000038-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2024"},{"label":"Revenue","value":"$364.3 million"},{"label":"Net income","value":"Net loss before non-controlling interest was $24.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}